Western Union Collaborates with Leading French Fintech Linxo to Launch Digital Money Transfers
29.6.2021 14:27:00 EEST | Business Wire | Press release
Western Union, a leader in cross-border, cross-currency money movement and payments, has collaborated with Linxo, a leading budget management and bank account aggregation application in France, to enable users to make local and cross-border payments through Western Union’s platform.
Linxo’s customers can now make and manage money transfers through Western Union’s platform, quickly, conveniently, and reliably, 24/7. Users can fund their transfers through their bank account or card, and have their funds paid out into billions of bank accounts and millions of mobile wallets in approximately 125 countries, or more than half a million retail locations in more than 200 countries and territories.
“We are pleased to be joining forces with Linxo, offering the 3.5 million users of this innovative app access to the broadest digital global network coverage within the cross-border person-to-person payment sector,” said Massimiliano Alvisini, Head of Europe, CIS, and Africa Network at Western Union. “In France, and across the world, we partner with fintechs, banks and post offices, offering their customers flexibility and trust underpinned by technology, customer experience and compliance,” he said.
Established in 2010, Linxo is a pioneering account aggregation fintech, that optimizes bank account and transaction management for its users. The Linxo application is available in both free and premium versions on the Apple App Store and on Google Play.
“By integrating the Western Union platform into our Linxo Marketplace, we are providing our users with a new and seamless customer experience thanks to enhanced functionalities for the management of their financial assets from a single space: consultation and management of accounts, sending or transferring money to their families and loved ones,” comments Bruno Van Haetsdaele, CEO and Co-Founder of Linxo Group. “Our ambition was to create a virtuous and open ecosystem. With the integration of the Western Union platform, this is now a reality. And we will continue to integrate new value-added services to provide our users with a quality service that exceeds their expectations within the Linxo application.”
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows, and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect businesses, financial institutions, governments, and consumers through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and over half a million-retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com
About Linxo
Linxo Group is a subsidiary of Crédit Agricole Payment Services, which {harnesses} Crédit Agricole Group’s expertise in marketing, innovation, processing and interbank representation. Since 2010, Linxo Group has been developing and marketing solutions for account aggregation, payment initiation and personal finance management.
The platform of its subsidiary Oxlin, a payment institution authorised by the ACPR [French Prudential Supervision and Resolution Authority], provides all the technology to access banking data and initiate transfers (services regulated by the Revised European Payment Services Directive no. 2, known as PSD2), with the customer's consent and in a totally secure manner.
The services it offers range from API (Application Program Interface) bricks to complete white-label mobile app solutions covering the needs of start-ups as well as banks and insurance companies. These solutions enable the development of new services and new sources of revenue from multiple use cases: budget management, pathways to credit grants, accounting, loyalty, etc.
Its mobile application Linxo, which is already installed and used by more than 3 million people in France, is an intelligent financial assistant, which allows everyone to have an overview of their finances and to simplify the management of their money.
The company has 85 employees, mainly in Aix-en-Provence and in the Crédit Agricole Villages in Paris and Sophia Antipolis.
WU-G
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005637/en/
Contact information
Media contacts:
Nicholas Mandalas
Nicholas.Mandalas@wu.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
